Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions.

A compound of formula (Ic)

##STR00001## wherein X.sup.2 represents a —CO—NR.sub.k— group, wherein R.sub.k represents a hydrogen atom or a methyl group, a —NH—CO—NH— group, a —OCH.sub.2— group, a —CH(OH)— group, a —NH—CO— group, a —O— group, a —O—(CH.sub.2).sub.s—O—, a —CO— group, a —SO.sub.2— group, a divalent 5-membered heteroaromatic ring comprising 1, 2, 3 or 4 heteroatoms, —a NH—SO.sub.2— or a —SO.sub.2—NH— group; Y.sup.2 represents a hydrogen atom, a halogen atom, a hydroxyl group, a (C.sub.1-C.sub.4)alkoxy group, a

##STR00002##

a

##STR00003##

group, a

##STR00004##

group, a morpholinyl group, optionally substituted by a (C.sub.1-C.sub.4)alkyl group, a piperazinyl group, a piperidinyl group, or a —CR.sup.1R.sup.2R.sup.3 group, or any of its pharmaceutically acceptable salt.

A compound of formula (Ic)

##STR00001## wherein X.sup.2 represents a —CO—NR.sub.k— group, wherein R.sub.k represents a hydrogen atom or a methyl group, a —NH—CO—NH— group, a —OCH.sub.2— group, a —CH(OH)— group, a —NH—CO— group, a —O— group, a —O—(CH.sub.2).sub.s—O—, a —CO— group, a —SO.sub.2— group, a divalent 5-membered heteroaromatic ring comprising 1, 2, 3 or 4 heteroatoms, —a NH—SO.sub.2— or a —SO.sub.2—NH— group; Y.sup.2 represents a hydrogen atom, a halogen atom, a hydroxyl group, a (C.sub.1-C.sub.4)alkoxy group, a

##STR00002##

a

##STR00003##

group, a

##STR00004##

group, a morpholinyl group, optionally substituted by a (C.sub.1-C.sub.4)alkyl group, a piperazinyl group, a piperidinyl group, or a —CR.sup.1R.sup.2R.sup.3 group, or any of its pharmaceutically acceptable salt.

Provided herein are compounds that are useful in treating cancer.

Provided herein are compounds that are useful in treating cancer.

An ion-lithium battery that may include an anode, a cathode, and at least one out of an anode related self-healing combination and a solid electrolyte interphase (SEI) self-healing combination; wherein the SEI related self-healing combination comprises a SEI self-healing additive, a SEI forming moiety and a first linker for linking the SEI self-healing additive to the SEI forming moiety; and wherein the anode related self-healing combination comprises an anode self-healing additive, an anode connection functional group, and a second linker for linking the anode self-healing additive to the anode connection functional group.

Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions.

Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions.

The application relates to a series of 2-imino-6-methylhexahydropyrimidin-4-one derivatives and 3-imino-5-methyl-1,2,4-thiadiazinane 1,1-dioxide derivatives of formula (I), substituted by an arylaminophenyl or heteroarylaminophenyl moiety. The compounds are potent inhibitors of the growth and propagation of the Plasmodium falciparum parasite in human blood and thus useful as pharmaceutical agents for the treatment of malaria. ##STR00001##

The application relates to a series of 2-imino-6-methylhexahydropyrimidin-4-one derivatives and 3-imino-5-methyl-1,2,4-thiadiazinane 1,1-dioxide derivatives of formula (I), substituted by an arylaminophenyl or heteroarylaminophenyl moiety. The compounds are potent inhibitors of the growth and propagation of the Plasmodium falciparum parasite in human blood and thus useful as pharmaceutical agents for the treatment of malaria. ##STR00001##